These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9604807)

  • 1. Pharmacological approaches in the treatment of primary hyperoxaluria.
    Holmes RP
    J Nephrol; 1998; 11 Suppl 1():32-5. PubMed ID: 9604807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (L)-2-oxothiazolidine-4-carboxylate in the treatment of primary hyperoxaluria type 1.
    Holmes RP; Assimos DG; Wilson DM; Milliner DS
    BJU Int; 2001 Dec; 88(9):858-62. PubMed ID: 11851603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1.
    Fargue S; Rumsby G; Danpure CJ
    Biochim Biophys Acta; 2013 Oct; 1832(10):1776-83. PubMed ID: 23597595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.
    Dutta C; Avitahl-Curtis N; Pursell N; Larsson Cohen M; Holmes B; Diwanji R; Zhou W; Apponi L; Koser M; Ying B; Chen D; Shui X; Saxena U; Cyr WA; Shah A; Nazef N; Wang W; Abrams M; Dudek H; Salido E; Brown BD; Lai C
    Mol Ther; 2016 Apr; 24(4):770-8. PubMed ID: 26758691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous Oxalate Production in Primary Hyperoxaluria Type 1 Patients.
    Garrelfs SF; van Harskamp D; Peters-Sengers H; van den Akker CHP; Wanders RJA; Wijburg FA; van Goudoever JB; Groothoff JW; Schierbeek H; Oosterveld MJS
    J Am Soc Nephrol; 2021 Dec; 32(12):3175-3186. PubMed ID: 34686543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of primary hyperoxaluria: clues to innovative treatments.
    Dindo M; Conter C; Oppici E; Ceccarelli V; Marinucci L; Cellini B
    Urolithiasis; 2019 Feb; 47(1):67-78. PubMed ID: 30430197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pyridoxine can normalize oxaluria in idiopathic renal lithiasis].
    Jaeger P; Portmann L; Jacquet AF; Burckhardt P
    Schweiz Med Wochenschr; 1986 Dec; 116(50):1783-6. PubMed ID: 3798070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases.
    Lorenz EC; Lieske JC; Seide BM; Olson JB; Mehta R; Milliner DS
    Am J Kidney Dis; 2021 May; 77(5):816-819. PubMed ID: 32891627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
    Chetyrkin SV; Kim D; Belmont JM; Scheinman JI; Hudson BG; Voziyan PA
    Kidney Int; 2005 Jan; 67(1):53-60. PubMed ID: 15610227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I.
    Martin-Higueras C; Luis-Lima S; Salido E
    Mol Ther; 2016 Apr; 24(4):719-25. PubMed ID: 26689264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of (L)-cysteine and (L)-2-oxothiazolidine-4-carboxylic acid (OTZ) on urinary oxalate excretion: studies using a hyperoxaluric rat model.
    Baker PW; Rofe AM; Bais R
    J Urol; 1998 Jun; 159(6):2177-81. PubMed ID: 9598565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II.
    Monico CG; Persson M; Ford GC; Rumsby G; Milliner DS
    Kidney Int; 2002 Aug; 62(2):392-400. PubMed ID: 12110000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria.
    Lai C; Pursell N; Gierut J; Saxena U; Zhou W; Dills M; Diwanji R; Dutta C; Koser M; Nazef N; Storr R; Kim B; Martin-Higueras C; Salido E; Wang W; Abrams M; Dudek H; Brown BD
    Mol Ther; 2018 Aug; 26(8):1983-1995. PubMed ID: 29914758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of (L)-2-oxothiazolidine-4-carboxylate on urinary oxalate excretion.
    Holmes RP; Assimos DG; Leaf CD; Whalen JJ
    J Urol; 1997 Jul; 158(1):34-7. PubMed ID: 9186317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria.
    Monico CG; Olson JB; Milliner DS
    Am J Nephrol; 2005; 25(2):183-8. PubMed ID: 15849466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant.
    Lorenz EC; Lieske JC; Seide BM; Meek AM; Olson JB; Bergstralh EJ; Milliner DS
    Am J Transplant; 2014 Jun; 14(6):1433-8. PubMed ID: 24797341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glyoxylate synthesis, and its modulation and influence on oxalate synthesis.
    Holmes RP; Assimos DG
    J Urol; 1998 Nov; 160(5):1617-24. PubMed ID: 9783918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycolate determination detects type I primary hyperoxaluria in dialysis patients.
    Marangella M; Petrarulo M; Bianco O; Vitale C; Finocchiaro P; Linari F
    Kidney Int; 1991 Jan; 39(1):149-54. PubMed ID: 2002628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyridoxine-responsive PH1: treatment.
    Toussaint C
    J Nephrol; 1998; 11 Suppl 1():49-50. PubMed ID: 9604811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Primary hyperoxaluria].
    Cochat P; Fargue S; Bacchetta J; Bertholet-Thomas A; Sabot JF; Harambat J
    Nephrol Ther; 2011 Jul; 7(4):249-59. PubMed ID: 21636340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.